A nodal risk cutoff for whole pelvic radiotherapy for prostate cancer?

In their recent Review paper in The Lancet Oncology, Gert De Meerleer and colleagues take a comprehensive look at evidence for pelvic irradiation in patients with prostate cancer.1 Specifically, for clinically node-negative prostate cancer, the value of elective whole pelvic radiotherapy (WPRT) has been discussed at length. For patients with Roach nodal risk of at least 20%, the POP-RT trial showed significant improvement in biochemical control,...